Cognition Therapeutics Reports Q3 2026 Financial Results and Phase III Trial Updates
Cognition Therapeutics (CGTX) reported a net loss of $4.1 million for the third quarter of 2026, an improvement over the $4.9 million loss recorded in the same period last year. The company's loss per share improved to $0.04 compared to $0.06 in the prior year. As of September 30, 2026, the company held $31.5 million in cash and cash equivalents, providing an operational runway into the fourth quarter of 2027. Key clinical developments include alignment with the FDA on a Phase III registrational study for zervimesine to treat dementia with Lewy bodies. By using psychosis symptoms as a proxy for disease progression, the company has significantly optimized its trial design, reducing the estimated budget from $150 million to less than $75 million and lowering expected enrollment to fewer than 375 participants. Additionally, the company is progressing with its START study in Alzheimer's disease, with top-line results anticipated in the second half of 2027.
Topics: biotechnology clinical trials earnings report financial results net loss